Media stories about Puma Biotechnology (NASDAQ:PBYI) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Puma Biotechnology earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.3051924942016 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$0.75 Per Share (americanbankingnews.com)
- Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results (finance.yahoo.com)
- Puma Biotechnology Inc (PBYI) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Sell or Hold action?: Puma Biotechnology, Inc. (PBYI) (nasdaqexpress.com)
- Technical Indicators under Review – Puma Biotechnology (NASDAQ: PBYI) (stocktradingdesk.com)
Several research analysts have recently commented on PBYI shares. Royal Bank of Canada lowered their price objective on shares of Puma Biotechnology to $77.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 24th. Credit Suisse Group lowered their price objective on shares of Puma Biotechnology from $147.00 to $106.00 and set an “outperform” rating for the company in a research note on Wednesday, January 24th. Citigroup reissued a “buy” rating and issued a $164.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, January 3rd. ValuEngine lowered shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, Zacks Investment Research raised shares of Puma Biotechnology from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $103.11.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.27. The firm had revenue of $21.60 million during the quarter, compared to analysts’ expectations of $20.83 million. During the same quarter in the prior year, the firm earned ($1.22) EPS. equities research analysts anticipate that Puma Biotechnology will post -4.07 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Puma Biotechnology (PBYI) Given Media Sentiment Rating of 0.12” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/26/puma-biotechnology-pbyi-given-media-sentiment-rating-of-0-12.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.